1Cademy - Racial Disproportionality in Covid Clinical Trials

Concept

Racial Disproportionality in Covid Clinical Trials

Covid-19 clinical trials underrepresented racial minority groups as data from remdesivir trials have shown limited support for the safety and efficacy of the drug on racial minorities.
In the Adaptive Covid-19 Treatment Trial (ACTT-1) and Gilead-funded study, Black Americans accounted for only about 20% of the 1063 and 11% of the 396 patients respectively, despite the disproportionately high number of Covid-19 related mortalities where these trials were conducted.
Demographics of the clinical trials failed to reflect the demographics of Covid-19 morbidities and mortalities.
This research concluded that the lack of diversity in these trials may suggest that results are not generalizable to minority populations due to the disparities in health outcomes.

0

1

Updated 2020-10-05

Contributors are:

Who are from:

References